远大医药2024年年报

2024 2371820556172748182848688 Conyers & Dill Pearman Conyers Corporate Services (Bermuda) LimitedClarendon House, 2 Church StreetHamilton HM11Bermuda 1831712-1716 Clarendon House, 2 Church StreetHamilton HM11, Bermuda 993302 www.grandpharma.cn 20243.6% 100% 1020247020212021-2035Frost & Sullivan2025932025203022.7%20302602018Sirtex2020Telix Pharmaceutical LimitedTelixRDC2022®[90Y]2,00020245140%RDC 3IIIRDCTLX591-CDxIII7Telix30100RDCTLX250-CDxFDA CBT-001IIIGPN00833IIIGPN01768 (TP-030.25%)NDA Tarsus Pharmaceuticals, Inc.TarsusOC-01Frost & Sullivan202544020301,16619.8% STC3141Ryaltris®2024NOVASIGHTTMHPV16mRNAARC01IHPVmRNA ESG 2025®[90Y]STC3141II2025 + RDCITM-11IIICOMPETEGPN00289GPN01768 (TP-030.25%)NDASTC3141IINOVASYNC HYBRID SYSTEMTMNOVASYNCTMNOVASIGHT HYBRIDSYSTEMTMNOVASIGHTTMOC-01OC-02 (Simpinicline)RDCTLX250-CDxIIIGPN00833IIIRDCITM-11IIICOMPETE 4.86100%2.6100%Ryaltris®GPN00884ITarsus1,500GPN01768 (TP-03)RDCITM-11IIIGPN00884INDGPN00833 (APP13007)NDAFDARyaltris®NDAHPV-16ARC01 (A002)IND 99.84% 63231731154141®5®NOVASYNCTMIberisTMDEEPQUAKETMNeoNova®12OC-015®®®®®®[90Y]LavaTM®®®®®Q10 ccRCCTLX250-CDxIITM-1123SSTR+GEP-NETsIIICOMPOSE12SSTR+GEP-NETsIIICOMPETE(Investigational New DrugIND ®NOVASYNC HYBRID SYSTEMTM NOVASYNCTM Ryaltris®GSP 301 NS(New DrugApplicationNDAGPN00187IGPN00204INDIAPADISTC3141II CBT-001IIIGPN00884IGPN01360IIGPN00833IIIGPN01768 (TP-030.25%)NDAGPN00680 mRNA 16HPV-16ARC01I 17 3 11 100%Ryaltris® 90%GPN01768OC-01OC-02 SimpiniclineOC-02 100% 13020182602024 800SirtexTelixITMIsotope Technologies Munich SEITMRDC1268Ga177Lu131I90Y89Zr57RDC12 ®[90Y]GPN00289RDCIIITLX591-CDxTLX250-CDxGEP-NETsITM-11LavaTM®[90Y] ®[90Y] ®[90Y]SIRT5015(BCLC)NCCNESMO(European Association for the Study of the LiverEASL)National Institute for Health and Care ExcellenceNICECSCO202420232021 ®[90Y] ®[90Y]®7022507®4010®65.6%6087.4% ®FDA701,100®170®708516® ®[90Y]4532130 LavaTM LavaTMLavaTM220LavaTM ® +1000®92.5%95.8%+2024CSCO2024® RDC GPN00289 GPN00289 KonaTM KonaTMKonaTMFDA(Premarket ApprovalPMA) AuroLase® AuroLase®AuroLase®FDAPMA RDC 9 TLX591/TLX591-CDx TLX591(PSMA)RDC(rPFS)8.8IIITLX591-CDxPSMARDCTLX591TLX591-CDx19TLX591-CDxIII TLX250TLX250-CDxTLX250-CDxFDA(CT)(MRI)ccRCCTLX250-CDx(PET)ccRCC86%87%FDA70%93%T1accRCC4cmTLX250-CDx85%89%TLX250-CDxccRCCccRCCTLX250-CDxFDATLX250-CDxCAIXTLX250-CDxI/IIIIIIIIIITLX250II GEP-NETsITM-11/TOCscan® ITM-11TOCscan®ITM-11FDAEMAIIICOMPETESSTR+GEP-NETs I23SSTR+GEP-NETsIIICOMPOSE12SSTR+GEP-NETsIIICOMPETEGEP-NETsTOCscan® TLX101 TLX101RDCL1LAT-1FDAI/IITLX101I ITM-41 ITM-41177LuRDC 27201NOVASYNCTMDEEPQUAKETMNeoNova®IberisTM +2205060% RESTORE DEB®APERTO®OTWSAFEPAXNOVASIGHT HYBRID SYSTEMTM NOVASIGHTTMNOVASYNC HYBRID SYSTEMTM NOVASYNCTMPCI® RESTORE DEB® RESTORE DEB®JACCJournal of the American College of Cardiology Cardiovascular Interventions APERTO®OTW APERTO®OTWAPERTO®OTWAmerican Journal of Kidney Diseases NOVASIGHTTMNOVASYNCTM NOVASIGHTTM NOVASYNCTMIVUSOCTNOVASIGHTTMFDANOVASYNCTM NOVASIGHTTMNOVASIGHTTM ® IberisTM IberisTMCirculation35.5CERDN DEEPQUAKETM ≥50%DEEPQUAKETM NeoNova® aXess aXessESRDAVGaXessAPERTO®OTW Saturn Saturn CoRISMA CoRISMA mRNA ®®®® ARDS ®®®®® ® 2022-20232023-2024 20242021202120202020 ®®II®®IIIII ®®2LABAICS(1)ICSLABALAMAICS-LABAICS-LABALAMA®®(2)(3)®IIIARGON®®2443%®®ICSLABA12®®III®®26%22%19% 2022 ARDS GSP 301 NS GSP 301 NS12IIIGSP 301 NSPatanase®NS®NSGSP 301 NSNDA STC3141: STC3141Nature CommunicationsCritical CareARDSCOVID-19COVID-19ARDSIbARDSIbCOVID-19IIaII APAD: APADSTC3141II OTC 30 14 ® 2021202020192017 2024 OC-01 OC-01IIIOC-01Schirmer1020242023 GPN00833: FDAIIINDA GPN00153CBT-001: IICBT-001IIIIII GPN00136BRM421: BRM421IIIIIII GPN00884: GPN00884I GPN01768TP-03 GABA-ClGABA-ClFDAFDAIINDA 30141620 Q10 ® 202420242024AHA20212021202120212021 ® ®® 2024ST(2024)2024 ®Q10 2024202420242024(2021)2018 ® (2016)120172020202020202022 ® MRAmineralocorticoid receptorMRMR202420242022MRAMRAMRMRA2024 Jext® 2110 ® A22022 ESC/ERS2021®2022 mRNA mRNAmRNAmRNALNP16HPV-16ARC01 (A002)IHPVmRNALNPHPV-16E6 E7mRNATriMix®LNPTriMix® 1203006050 20 EU GMPREACHWCKFDAISOFSSC22000GRASHALALKOSHER 5025FDA 14040%500 11,644,890,00010,529,590,00010.6%12.8%2,468,375,0001,880,000,00031.3%34.0%Telix11,760,650,0001,717,250,0002.5%4.6% 816,210,000335,390,000148.3%2589,460,000217,450,000176.6%2226,750,000 1Telix707,721,000162,748,000 7,317,840,0006,813,240,0009.6%11,709,260,0001,374,620,00026.9%1®®®®2,704,300,0002,313,620,00019.3%12,176,240,0002,447,490,0009.3%1 3,510,840,0003,380,960,0005.9%12,762,280,0002,757,760,0002.2%1 3,256,890,0001,365,370,0002,567,630,0001,234,380,000689,260,000130,990,000 180,240,000205,150,000 2,273,960,000 3,454,590,000386,530,000 2,928,090,00098,390,000 5%(i)Grand Pharma Sphere Pte LimitedGrand Pharma Sphere(ii) Grand Pharma Sphere57.98%Grand Pharma Sphere16,630,00089,070,000 55%123,770,000106,430,000 1.Grand Pharma Sphere2.3. mRNAmRNA RDC2025 77052568% 0.3%